ProPhase Labs (ProPhase Labs) COGS-to-Revenue : 1.12 (As of Mar. 2024)

View and export this data going back to 1995. Start your Free Trial

What is ProPhase Labs COGS-to-Revenue?

ProPhase Labs's Cost of Goods Sold for the three months ended in Mar. 2024 was $4.07 Mil. Its Revenue for the three months ended in Mar. 2024 was $3.63 Mil.

ProPhase Labs's COGS to Revenue for the three months ended in Mar. 2024 was 1.12.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. ProPhase Labs's Gross Margin % for the three months ended in Mar. 2024 was -11.92%.

ProPhase Labs COGS-to-Revenue Historical Data

The historical data trend for ProPhase Labs's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs COGS-to-Revenue Chart

ProPhase Labs Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.74

0.68

0.47

0.42

0.63

ProPhase Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.46	0.51	0.72	1.87	1.12

ProPhase Labs COGS-to-Revenue Calculation

ProPhase Labs's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	28.145	/	44.384
	=	0.63

ProPhase Labs's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	4.067	/	3.634
	=	1.12

ProPhase Labs (NAS:PRPH) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

ProPhase Labs's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	4.067 / 3.634
	=	-11.92 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

ProPhase Labs COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

ProPhase Labs (ProPhase Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » COGS-to-Revenue

Comparable Companies

ACRS BNR VNRX MDXH BIOQ NOTV STIM FONR PSNL PRE TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

N/A

Address

711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530

Website

https://www.prophaselabs.com

ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.

Executives

Morse Robert A. Jr.	officer: Controller	711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White	officer: Chief Financial Officer	191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr	director	902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel	10 percent owner	C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus	10 percent owner	188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch	director	621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady	officer: Chief Accounting Officer	621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr	officer: Chief Operating Officer	PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard	10 percent owner	156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal	10 percent owner	THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank	director	104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin	director
Mark A. Burnett	10 percent owner	40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley	director, 10 percent owner, officer: Chairman, President, CEO	C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo	10 percent owner	17 WOLCOTT COURT, BOSTON MA 02136